Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis

C. Salvarani, R. Baricchi, D. Lasagni, L. Boiardi, R. Piccinini, C. Brunati, P. Macchioni, I. Portioli

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective. To investigate the effects of desferrioxamine (DFO) infusion on chronic disease anemia (CDA) of rheumatoid arthritis (RA) by evaluating interleukin-6 (IL-6) and erythropoietin (EPO) production. Patients and methods. Five patients with RA and CDA (group I) were treated with DFO, 500 mg daily, through a continuous 10-h subcutaneous infusion 5 days a week for 4 weeks. One month after withdrawal, DFO was resumed in all five group I patients (group II) with an increase to 1 g daily following the previous treatment schedule. Clinical and laboratory parameters were evaluated weekly during the two study periods. Serum EPO was measured by radioimmunoassay. IL-6 was detected by the enzyme-linked immunoabsorbent assay method. Results. No significant variations in hematological parameters, IL-6 or EPO levels were observed in group I patients. After 1 week of DFO 1 g daily, reticulocyte counts and EPO improved significantly. Hemoglobin and hematocrit rose significantly after 3 weeks of 1 g daily DFO therapy. Four weeks after DFO withdrawal, EPO, reticulocyte counts, hemoglobin and hematocrit returned to baseline levels. A significant improvement in the clinical parameters of disease activity was observed, particularly in group II patients. Conclusion. DFO improves CDA in RA patients. The beneficial effects on erythropoiesis seem to be related to improved EPO responsiveness to the anemia.

Original languageEnglish
Pages (from-to)45-48
Number of pages4
JournalRheumatology International
Volume16
Issue number2
Publication statusPublished - 1996

Fingerprint

Deferoxamine
Erythropoietin
Anemia
Rheumatoid Arthritis
Chronic Disease
Reticulocyte Count
Interleukin-6
Hematocrit
Therapeutics
Hemoglobins
Subcutaneous Infusions
Erythropoiesis
Radioimmunoassay
Appointments and Schedules
Enzymes
Serum

Keywords

  • Chronic disease anemia
  • Desferrioxamine therapy
  • Erythropoietin
  • Interleukin-6
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis. / Salvarani, C.; Baricchi, R.; Lasagni, D.; Boiardi, L.; Piccinini, R.; Brunati, C.; Macchioni, P.; Portioli, I.

In: Rheumatology International, Vol. 16, No. 2, 1996, p. 45-48.

Research output: Contribution to journalArticle

Salvarani, C, Baricchi, R, Lasagni, D, Boiardi, L, Piccinini, R, Brunati, C, Macchioni, P & Portioli, I 1996, 'Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis', Rheumatology International, vol. 16, no. 2, pp. 45-48.
Salvarani, C. ; Baricchi, R. ; Lasagni, D. ; Boiardi, L. ; Piccinini, R. ; Brunati, C. ; Macchioni, P. ; Portioli, I. / Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis. In: Rheumatology International. 1996 ; Vol. 16, No. 2. pp. 45-48.
@article{3d471a0c198a42f8a5ff589d7a4959e7,
title = "Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis",
abstract = "Objective. To investigate the effects of desferrioxamine (DFO) infusion on chronic disease anemia (CDA) of rheumatoid arthritis (RA) by evaluating interleukin-6 (IL-6) and erythropoietin (EPO) production. Patients and methods. Five patients with RA and CDA (group I) were treated with DFO, 500 mg daily, through a continuous 10-h subcutaneous infusion 5 days a week for 4 weeks. One month after withdrawal, DFO was resumed in all five group I patients (group II) with an increase to 1 g daily following the previous treatment schedule. Clinical and laboratory parameters were evaluated weekly during the two study periods. Serum EPO was measured by radioimmunoassay. IL-6 was detected by the enzyme-linked immunoabsorbent assay method. Results. No significant variations in hematological parameters, IL-6 or EPO levels were observed in group I patients. After 1 week of DFO 1 g daily, reticulocyte counts and EPO improved significantly. Hemoglobin and hematocrit rose significantly after 3 weeks of 1 g daily DFO therapy. Four weeks after DFO withdrawal, EPO, reticulocyte counts, hemoglobin and hematocrit returned to baseline levels. A significant improvement in the clinical parameters of disease activity was observed, particularly in group II patients. Conclusion. DFO improves CDA in RA patients. The beneficial effects on erythropoiesis seem to be related to improved EPO responsiveness to the anemia.",
keywords = "Chronic disease anemia, Desferrioxamine therapy, Erythropoietin, Interleukin-6, Rheumatoid arthritis",
author = "C. Salvarani and R. Baricchi and D. Lasagni and L. Boiardi and R. Piccinini and C. Brunati and P. Macchioni and I. Portioli",
year = "1996",
language = "English",
volume = "16",
pages = "45--48",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis

AU - Salvarani, C.

AU - Baricchi, R.

AU - Lasagni, D.

AU - Boiardi, L.

AU - Piccinini, R.

AU - Brunati, C.

AU - Macchioni, P.

AU - Portioli, I.

PY - 1996

Y1 - 1996

N2 - Objective. To investigate the effects of desferrioxamine (DFO) infusion on chronic disease anemia (CDA) of rheumatoid arthritis (RA) by evaluating interleukin-6 (IL-6) and erythropoietin (EPO) production. Patients and methods. Five patients with RA and CDA (group I) were treated with DFO, 500 mg daily, through a continuous 10-h subcutaneous infusion 5 days a week for 4 weeks. One month after withdrawal, DFO was resumed in all five group I patients (group II) with an increase to 1 g daily following the previous treatment schedule. Clinical and laboratory parameters were evaluated weekly during the two study periods. Serum EPO was measured by radioimmunoassay. IL-6 was detected by the enzyme-linked immunoabsorbent assay method. Results. No significant variations in hematological parameters, IL-6 or EPO levels were observed in group I patients. After 1 week of DFO 1 g daily, reticulocyte counts and EPO improved significantly. Hemoglobin and hematocrit rose significantly after 3 weeks of 1 g daily DFO therapy. Four weeks after DFO withdrawal, EPO, reticulocyte counts, hemoglobin and hematocrit returned to baseline levels. A significant improvement in the clinical parameters of disease activity was observed, particularly in group II patients. Conclusion. DFO improves CDA in RA patients. The beneficial effects on erythropoiesis seem to be related to improved EPO responsiveness to the anemia.

AB - Objective. To investigate the effects of desferrioxamine (DFO) infusion on chronic disease anemia (CDA) of rheumatoid arthritis (RA) by evaluating interleukin-6 (IL-6) and erythropoietin (EPO) production. Patients and methods. Five patients with RA and CDA (group I) were treated with DFO, 500 mg daily, through a continuous 10-h subcutaneous infusion 5 days a week for 4 weeks. One month after withdrawal, DFO was resumed in all five group I patients (group II) with an increase to 1 g daily following the previous treatment schedule. Clinical and laboratory parameters were evaluated weekly during the two study periods. Serum EPO was measured by radioimmunoassay. IL-6 was detected by the enzyme-linked immunoabsorbent assay method. Results. No significant variations in hematological parameters, IL-6 or EPO levels were observed in group I patients. After 1 week of DFO 1 g daily, reticulocyte counts and EPO improved significantly. Hemoglobin and hematocrit rose significantly after 3 weeks of 1 g daily DFO therapy. Four weeks after DFO withdrawal, EPO, reticulocyte counts, hemoglobin and hematocrit returned to baseline levels. A significant improvement in the clinical parameters of disease activity was observed, particularly in group II patients. Conclusion. DFO improves CDA in RA patients. The beneficial effects on erythropoiesis seem to be related to improved EPO responsiveness to the anemia.

KW - Chronic disease anemia

KW - Desferrioxamine therapy

KW - Erythropoietin

KW - Interleukin-6

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0029797639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029797639&partnerID=8YFLogxK

M3 - Article

C2 - 8853224

AN - SCOPUS:0029797639

VL - 16

SP - 45

EP - 48

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 2

ER -